menu search

VOR / How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. Read More
Posted: Mar 28 2023, 11:29
Author Name: Zacks Investment Research
Views: 110526

VOR News  

Vor Bio to Participate in Upcoming Investor Conferences

By GlobeNewsWire
September 25, 2023

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that more_horizontal

Vor Bio to Participate in Upcoming Investor Conferences

By GlobeNewsWire
April 18, 2023

Vor Bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that more_horizontal

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

By Zacks Investment Research
March 28, 2023

How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%

The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not more_horizontal

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

By Seeking Alpha
March 27, 2023

Vor Biopharma: Very Interesting Idea For Improving CAR-T Through Stem Cells

Vor Biopharma Inc. is the brainchild of Dr. Siddhartha Mukherjee. Its core idea is to make CAR-Ts safer by using stem cells. more_horizontal

Vor Bio Announces Q4 And FY 2022 Results

By Pulse2
March 24, 2023

Vor Bio Announces Q4 And FY 2022 Results

Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, reported its financial results for the three-month period and full year t more_horizontal

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

By GlobeNewsWire
April 25, 2022

Vor Bio to Present at Keystone Symposia Precision Genome Engineering Meeting

Presentations showcase breadth of Vor Bio's multiplex editing capability including base editing of human hematopoietic stem and progenitor cells (HSPC more_horizontal


Search within

Pages Search Results: